spacer
home > ict > spring 2008 > materialising markets
PUBLICATIONS
International Clinical Trials

Materialising Markets

Jerry Boxall of ACM-Pivotal Europe explores the pros and cons of clinical research in the emerging markets from the point of view of a global clinical trials organisation

As the global market continues to expand, pharmaceutical companies must make decisions about which of the key emerging regions to focus on when it comes to clinical trials. Expansion into new markets is nothing new for the pharmaceutical industry, and within Europe we have seen the countries of Central and Eastern Europe (CEE) emerge as major centres for clinical research over the past decade. As with every new opportunity, there are risks associated with conducting research in emerging regions, and a look back at the lessons learnt from the CEE region may be a valuable exercise in identifying potential threats in new locations across the globe.

There is no doubt that momentum is gathering in favour of the emerging economies. According to the Financial Times, the proportion of principal investigators registered with the US Food and Drug Administration – but based outside the US and Western Europe – rose from five per cent in 1997 to 29 per cent last year, with the fastest growth coming from India, China, Russia and Argentina in the past five years (1). These regions are prime clinical trial locations; they offer low cost services, skilled investigators, and a large, diverse pool of highly compliant patients.

Companies that have already explored the opportunities in these new locations have increased patient recruitment by 20 to 30 per cent, whilst also reducing costs. In Phase III trials, research shows that it is common for results to come in six or seven months quicker than in domestic markets – all elements that help to get the drug to market and generate revenue more quickly. However, the globalisation of clinical trials has faced increasing scrutiny over issues such as the quality of data, ethical considerations and the safety of the patients involved.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jerry Boxall is a Member of the Institute of Clinical Research (ICR) and is Managing Director, Europe, of ACM-Pivotal. Trained as a Biomedical Scientist, Jerry has over 25 years’ experience in this field. For the past 15 years he has held senior central laboratory posts both in the UK and Europe. Jerry has been heavily involved in the establishment of both European and global central laboratories in Germany, France, Denmark, the Netherlands and the UK. Jerry joined the ACM-Pivotal team from CRL-Medinet in June 2000 as Head of European Operations, and took over as Managing Director, Europe, in January 2005
spacer
Jerry Boxall
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala Introduces CAB100 Industrial Cabinet for Cleanrooms

Vaisala, a global leader in weather, environmental, and industrial measurements, launches its newest offering for centralized environmental monitoring in cleanrooms: The CAB100 integrates Vaisala’s world-class instruments for monitoring parameters into a simple, pre-configured enclosure.
More info >>

White Papers

Personalised Medicine - Pharma and Dx Firms Share Wider Horizons

DiagnostikNet-BB

Personalised medicine might be a popular catch-phrase at the moment, but the term often causes confusion, as there is still no uniform definition for it. The expression can include areas as diverse as the measurement of individual risk, early detection using biomarker testing, stratification of patients suffering from a disease and predictions about its course.
More info >>

 
Industry Events

Clinical Trial Supply Global Forum

20-22 May 2019, Brussels, Belgium

You can’t get a drug to market without a clinical trial. You can’t run a clinical trial without product supply. We understand that your role is critical in ensuring the on time and efficient development of the next life saving drug and we know that this makes your time precious. In 2019 we have condensed everything you need to advance your Clinical Trial Supply into three jam packed days. The industry's most interactive and solution focused CTS forum features deep dive workshops, live polls, panel debates, round table discussions and exclusive key note case studies to ensure that you leave with the industry's best solutions and strategies to transform your clinical trial supply. If there is ONE Clinical Trial Supply conference that you attend in 2019, make sure that it is this one.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement